Showing 145 to 152 of 152 results
Pfizer's 2025 Forecast Meets Expectations Amidst Medicare Changes and Investor Scrutiny
Pfizer projects 2025 profits near analyst estimates, anticipating stable Covid-19 product sales despite a \$1 billion revenue reduction from Medicare changes and ongoing investor pressure following a 12% share decline this year.
Pfizer's 2025 Forecast Meets Expectations Amidst Medicare Changes and Investor Scrutiny
Pfizer projects 2025 profits near analyst estimates, anticipating stable Covid-19 product sales despite a \$1 billion revenue reduction from Medicare changes and ongoing investor pressure following a 12% share decline this year.
Progress
36% Bias Score
Pfizer's Dutch Subsidiary Reports $11.4 Billion Profit Amidst Reduced COVID-19 Vaccine Sales
Pfizer's Dutch subsidiary reported an $11.4 billion profit for the fiscal year ending November 2023, down from previous years due to reduced COVID-19 vaccine and medication sales, but comparable to pre-pandemic levels; the company's revenue decreased from $74.4 billion in 2022 to $46.9 billion in 20...
Pfizer's Dutch Subsidiary Reports $11.4 Billion Profit Amidst Reduced COVID-19 Vaccine Sales
Pfizer's Dutch subsidiary reported an $11.4 billion profit for the fiscal year ending November 2023, down from previous years due to reduced COVID-19 vaccine and medication sales, but comparable to pre-pandemic levels; the company's revenue decreased from $74.4 billion in 2022 to $46.9 billion in 20...
Progress
40% Bias Score
Spain Unveils €8 Billion Pharmaceutical Strategy to Boost Domestic Production and Access
Spain's Ministry of Health presented a 2024-2028 pharmaceutical industry strategy to strengthen domestic production, promote innovation, ensure equitable access to medicines, and enhance the National Health System's sustainability, involving €8 billion investment and 4,500 new jobs.
Spain Unveils €8 Billion Pharmaceutical Strategy to Boost Domestic Production and Access
Spain's Ministry of Health presented a 2024-2028 pharmaceutical industry strategy to strengthen domestic production, promote innovation, ensure equitable access to medicines, and enhance the National Health System's sustainability, involving €8 billion investment and 4,500 new jobs.
Progress
4% Bias Score
Kennedy's Potential Impact on US Health Policy
Analysis of Robert F. Kennedy Jr.'s potential impact on US health policies if appointed as Secretary of Health and Human Services, focusing on his controversial views on vaccines and pharmaceutical companies.
Kennedy's Potential Impact on US Health Policy
Analysis of Robert F. Kennedy Jr.'s potential impact on US health policies if appointed as Secretary of Health and Human Services, focusing on his controversial views on vaccines and pharmaceutical companies.
Progress
40% Bias Score
McKinsey to Pay $650 Million in Opioid Settlement
McKinsey & Company agreed to pay $650 million to settle federal charges for its role in boosting OxyContin sales, including $2 million to Virginia's Medicaid Fraud Control Unit; a former partner pleaded guilty to obstruction of justice.
McKinsey to Pay $650 Million in Opioid Settlement
McKinsey & Company agreed to pay $650 million to settle federal charges for its role in boosting OxyContin sales, including $2 million to Virginia's Medicaid Fraud Control Unit; a former partner pleaded guilty to obstruction of justice.
Progress
52% Bias Score
Eli Lilly Stock Rebounds After Initial Post-Election Dip
Post-election, Eli Lilly's stock initially fell 6% due to concerns over President-elect Trump's choice for Health and Human Services, but has since rebounded due to meetings between Eli Lilly's CEO and the President-elect, coupled with Elon Musk's public support for affordable weight-loss drugs, ind...
Eli Lilly Stock Rebounds After Initial Post-Election Dip
Post-election, Eli Lilly's stock initially fell 6% due to concerns over President-elect Trump's choice for Health and Human Services, but has since rebounded due to meetings between Eli Lilly's CEO and the President-elect, coupled with Elon Musk's public support for affordable weight-loss drugs, ind...
Progress
44% Bias Score
HIMS Stock Rises Despite Volatility, Driven by Diverse Revenue Streams
Hims & Hers Health (HIMS) stock price rose from $23.50 in July to $32.50 currently, despite September's dip below $14; its compounded semaglutide injections, representing under 10% of revenue, contribute to volatility, while the company shows continued strength.
HIMS Stock Rises Despite Volatility, Driven by Diverse Revenue Streams
Hims & Hers Health (HIMS) stock price rose from $23.50 in July to $32.50 currently, despite September's dip below $14; its compounded semaglutide injections, representing under 10% of revenue, contribute to volatility, while the company shows continued strength.
Progress
40% Bias Score
Kalundborg: Wegovy's Paradox
Kalundborg, a small Danish town, is a major production hub for Novo Nordisk's weight-loss drug, Wegovy. Despite substantial investment, the town struggles to attract residents and faces various social and infrastructural challenges.
Kalundborg: Wegovy's Paradox
Kalundborg, a small Danish town, is a major production hub for Novo Nordisk's weight-loss drug, Wegovy. Despite substantial investment, the town struggles to attract residents and faces various social and infrastructural challenges.
Progress
0% Bias Score
Showing 145 to 152 of 152 results